WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 USD
arrow_upward
+0,48%(+0,060) 1D
16. lis, 16:00:00 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za WXXWY...
Otvori
12,29 USD
Najviša
12,56 USD
Najniža
12,20 USD
Trž. kap.
198,43 mlr.
Prosj. kol.
61,89 tis.
Količina
110,85 tis.
52-tjed. najviša
14,80 USD
52-tjed. najniža
7,30 USD
Beta
0,01
Dionice u optjecaju
2,06 mlr.
Broj djelatnika
15 tis.
Otvori
12,29 USD
Najviša
12,56 USD
Najniža
12,20 USD
Trž. kap.
198,43 mlr.
Prosj. kol.
61,89 tis.
Količina
110,85 tis.
52-tjed. najviša
14,80 USD
52-tjed. najniža
7,30 USD
Beta
0,01
Dionice u optjecaju
2,06 mlr.
Broj djelatnika
15 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Financije.hr
·
prije 2 dana
Wall Street pred otvaranjem: Rotacija iz tehnologije jača, Dow preuzima vodstvo
GlobeNewswire
·
prije 33 minute
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Business Wire
·
prije 1 sat
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR to Hold Listing Ceremony and First Investor Day at the Nasdaq Tower on Oct. 26; Three New Robotics Product Offerings Launched
Yahoo! Finance Canada
·
prije 18 minuta
CABA,TRIN,RPC,FFIN,NXRT,GO,CULP,BLCO,VSNT,KWY,FRST,VIRC,ENTX,BLIN,GRNT,SSP,GAIA,NRGV,AFCG,APCX,THRY,KLTR,BETR | Stock Prices | Quote Comparison
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Wuxi Biologics Cayman ADR – informacije
Glavni izvršni direktorZhisheng Chen
Zaposlenici14,7 tis.
Osnovano2010
Sjedište-
Sektor-
Web-lokacijawuxibiologics.com